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triglycerides. Apo-CIII glycoisoforms 
after bariatric surgery were assessed in 
relation to glycomic changes. Bariatric 
surgery appears to alter the isoform 
distribution in the direction of the non-
obese.1 Most health care professionals 
know of Helicobacter pylori and its 
association with gastric ulceration 
and gastritis. Biomarkers such as 
Helicobacter pylori antibodies, basal and 
stimulated gastrin-17 and pepsinogen 
I and II have also been investigated as 
potential replacements of preoperative 
esophagogastroduodenoscopy for bariatric 
surgery, where they showed promise as 
surrogate markers.2 The complement 
pathways such as the classical and 
alternative pathways are well known for 
their role in immune regulation. Plasma 
complement factor 3 showed a strong 
association with post-bariatric surgery 
insulin resistance.3 Epithelial intermediate 
filament proteins or cytokeratins are 
useful for immunohistochemistry and 
tumour detection diagnostics. In 2008 
levels of cytokeratin 18 fragments have 
been suggested to potentially be useful 
as a novel biomarker of non-alcoholic 
fatty liver disease (NAFLD) in bariatric 
patients.4 The receptor for advanced 
glycation end products or RAGE has 
been implicated in various diseases. 
The soluble form of RAGE (sRAGE) 
has been investigated in various clinical 
scenarios for associations and diagnostic 
utility. sRAGE may help identify those 
individuals who are expected to gain 
greater benefit from bariatric surgery.5 
Neutrophil gelatinase-associated lipocalin 
or NGAL is a newer marker for the 
diagnosis of kidney disease and in general 
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obesity afflicts a high number of individuals worldwide. Also, looking further into the local situation 
in Malta, there are alarming national 
statistics with regards to Maltese 
prevalence of obesity. This in turn poses 
a significant burden on health care 
given obesity is associated with multiple 
co-morbidities. Notable examples 
include type 2 diabetes, dyslipidemia, 
atherosclerosis, non-alcoholic 
steatohepatitis and sleep apnoea. When 
dietary, exercise and pharmacological 
regimes fail, certain patients may meet 
the criteria for Bariatric surgery which 
usually encompass those with morbid 
obesity having a BMI greater or equal 
to 40kg/m2 or a BMI greater or equal to 
35kg/m2 which is medically complicated. 
Bariatric surgery has the potential to 
result in remission of type 2 diabetes.
During my bariatrics attachment at 
Mater Dei Hospital with Mr Benedict 
Axisa’s bariatric team between October 
to November 2018 I had the pleasure of 
meeting the bariatric multidisciplinary 
assessment team which involved the 
surgical team, psychologist, dietician, 
anaesthetic teams, members of the 
sleep apnoea studies team and nursing 
teams who provide holistic patient 
management. The lead bariatric dietician 
and lead psychologist also host joint 
support groups on Mondays. During 
my attachment the Health Promotion 
and Disease Prevention Directorate and 
the European Association for the Study 
of Obesity (EASO) hosted a training 
course for health care professionals in the 
management of adult obesity which was 
very well received.
This short article looks further into 
relevant biochemical blood tests at 
the crossroads of chemical pathology 
and bariatrics. Standard biochemical 
laboratory tests such as lipid panels, 
LFTs and HbA1c, amongst others, guide 
general assessment and management 
of obesity. Clinical biochemistry tests 
may also be used to rule out secondary 
causes of obesity such as for example 
Cushing’s syndrome, hypothyroidism 
and polycystic ovarian syndrome. 
These could include TFTs and a urinary 
24-hour collection for free cortisol and 
hormonal assessments including LH, FSH 
and testosterone levels. Post-operative 
assessment of micronutrient and vitamin 
deficiencies may also rely on clinical 
biochemistry laboratory input. These 
deficiencies are even more likely to occur 
in malabsorptive procedures.
Certain other substances that are 
found in a person’s blood may serve 
as biomarkers to guide diagnosis, 
management and occasionally help make 
prognostications. A brief literature review 
was conducted on PubMed articles in 
October 2018 taking as inclusion criteria 
articles having concurrently both the 
terms ‘biomarker’ and ‘bariatric’ in the 
title. Six publications are outlined below. 
This in turn looks at the crossroads of 
bariatrics and chemical pathology from a 
more academic perspective.
The body has various apolipoproteins 
that participate in lipoprotein metabolic 
pathways. Apolipoprotein C3 (Apo-
CIII) has been described as acting as 
an inhibitor of lipoprotein lipase and 
hepatic lipase and is known to play a 
role in the regulation of metabolism of 
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has been advocated as playing a role in 
the earlier detection of kidney injury. A 
paper was also written in 2013 about the 
putative benefit of using urinary NGAL in 
earlier detection of acute kidney injury in 
specifically bariatric patients.6
A separate literature review was 
again conducted via PubMed database 
this time expanding inclusion criteria 
to the terms ‘biomarker’ and ‘obesity’ 
in the title. This in turn yielded a far 
more extensive range of published 
papers in the literature. To date 
numerous papers were published 
detailing potential associations between 
biomarkers and obesity.
Leptin has been extensively studied 
as a hormone that regulates hunger 
together with energy consumption. 
Adiponectin is an adipokine produced 
by adipose tissue and plays a role in 
glucose and fatty acid metabolism. 
Larsen et al. suggest that the leptin to 
adiponectin (L:A) ratio can be used as 
a surrogate marker to uncover at an 
earlier stage metabolic derangements 
in obese individuals.7 In another 
publication Tacke et al. discussed 
adipokine Wnt1 inducible signalling 
pathway protein 1 (WISP-1)/CCN4 as 
a potential novel obesity biomarker.8 
N-Acylethanolamines play various 
roles in energy expenditure. Fanelli 
et al. wrote about the usefulness of 
N-Acylethanolamine profiling in 
obesity.9 Identification of miRNA 
biomarkers as a differentiation factor 
between obesity and metabolic 
syndrome would provide greater insights 
into pathophysiology. O’Neill et al. 
identified miR-758-3p, as related to 
cholesterol efflux regulatory protein/
ATP-binding cassette transporter 
expression, which could aid diagnosis of 
developing metabolic syndrome in the 
setting of obesity.10
Other interesting assessment 
methods have also been reported 
such as the measurement of the islet 
amyloid polypeptide, amylin, via the 
use of an amperometric immunoassay 
screen-printed carbon electrode and 
electropolymerized carboxylated 
polypyrrole.11 In keeping with this, the 
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immunohistochemical expression of 
PGC1 alpha was assessed from fat tissue 
specimens collected during bariatric 
surgery to elucidate patterns. The 
authors concluded that PGC1alpha may 
potentially constitute a therapeutic and 
preventive marker in obesity-related 
comorbidities.12
This is just a snapshot of some 
implicated biomarkers since other 
candidate substances have been 
described earlier in the literature. 
